CVRx

CVRX

Market cap $259M

CVRx (CVRX) Q2 Revenue Jumps 15%

Call Start: 16:30 January 1, 0000 5:09 PM ET CVRx, Inc. (NASDAQ:CVRX ) Q2 2025 Earnings Conference Call August 04, 2025, 04:30 PM ET Company Participants Jared Oasheim - Chief Financial Officer Kevin Hykes - President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C., Research Division Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division John Edward Young - Canaccord Genuity Corp., Research Division Rohin Kirit Patel - JPMorgan Chase & Co, Research Division Ross Everett Osborn - Cantor Fitzgerald & Co., Research Division Samantha Munoz - Piper Sandler & Co., Research Division Michael Vallie - Unidentified Company Operator Good afternoon, ladies and gentlemen.

CVRx (CVRX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.65 per share a year ago.

MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2025.

MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast.

CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting. CMS is also soliciting comments about the need for a Level 6 Neurostimulator APC. We expect CMS will publish the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule in November, which is expected to take effect on January 1, 2026.

CVRx offers a unique, FDA-approved heart failure therapy with Medicare reimbursement, positioning it for significant market adoption and growth. The recent share price drop is an overreaction to sales force restructuring and reimbursement fears, while earnings and revenue estimates remain stable. Current valuation is deeply discounted versus sector peers, despite high-teens revenue growth and clear operating leverage potential as sales ramp up.

MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025. The Company is scheduled to present at 10:00am Central Time the same day via webcast.